Novartis Continues RNA & Neuroscience Growth Strategy With $12B Avidity Bio Acquisition
Avidity Biosciences brings to Novartis three RNA therapies in pivotal testing for rare neuromuscular diseases along with the technology that produced them. This platform develops drugs in a new class of targeted medicines offering potential to expand the delivery of RNA treatments beyond the liver. The post Novartis Continues RNA & Neuroscience Growth Strategy With…